Racial and ethnic disparities in human papillomavirus (HPV) vaccine uptake among United States adults, aged 27–45 years
Natalie L. Rincon,Kelsey Rae McDowell,Darien Weatherspoon,Tiarney D. Ritchwood,Daniel J. Rocke,Eric Adjei Boakye,Nosayaba Osazuwa-Peters,Natalie L. RinconKelsey Rae McDowellDarien WeatherspoonTiarney D. RitchwoodDaniel J. RockeEric Adjei BoakyeNosayaba Osazuwa-Petersa Trinity College of Arts & Sciences,Duke University,Durham,NC,USAb REACH Equity Summer Undergraduate Research Program (RESURP),Duke University School of Medicine,Durham,NC,USAc School of Nursing,University of North Carolina-Chapel Hill,Chapel Hill,NC,USAd Department of Dental Public Health,University of Maryland School of Dentistry,Baltimore,MD,USAe Department of Family Medicine and Community Health,Duke University School of Medicine,Durham,NC,USAf Department of Head and Neck Surgery & Communication Sciences,Duke University School of Medicine,Durham,NC,USAg Duke Cancer Institute,Duke University,Durham,NC,USAh Department of Public Health Sciences,Henry Ford Health System,Detroit,MI,USAi Department of Otolaryngology–Head and Neck Surgery,Henry Ford Health System,Detroit,MI,USAj Department of Population Health Sciences,School of Medicine,Duke University,Durham,NC,USA
DOI: https://doi.org/10.1080/21645515.2024.2313249
2024-03-28
Human Vaccines & Immunotherapeutics
Abstract:In 2018, the Food and Drug Administration expanded the age of eligibility for the human papillomavirus (HPV) vaccine to 27 to 45 years. However, it is unclear if there are racial/ethnic disparities in HPV vaccine uptake for this age-group following this expanded recommendation. We aimed to identify any disparities in HPV vaccine in 27 to 45 year-olds based on sociodemographic factors. We analyzed nationally representative, cross-sectional data from the 2019 National Health Interview Survey ( n = 9440). Logistic regression models estimated the odds of vaccine uptake (receipt of ≥1 vaccine dose) based on sociodemographic factors. Participants were mostly Non-Hispanic Whites (60.7%) and females (50.9%). In adjusted models, females had over three times greater odds of vaccine uptake compared to males (aOR = 3.58; 95% CI 3.03, 4.23). Also, compared to Non-Hispanic Whites, Non-Hispanic Blacks were 36% more likely (aOR = 1.36; 95% CI 1.09, 1.70), and Hispanics were 27% less likely (aOR = 0.73; 95% CI 0.58, 0.92) to receive the vaccine. Additionally, individuals without a usual place of care had lower odds of vaccine uptake (aOR = 0.72; 95% CI 0.57, 0.93), as were those with lower educational levels (aOR high school = 0.62; 95% CI 0.50, 0.78; aOR some college = 0.83; 95% CI 0.70, 0.98). There are disparities in HPV vaccine uptake among 27 to 45 year-olds, and adult Hispanics have lower odds of receiving the vaccine. Given the vaccine's importance in cancer prevention, it is critical that these disparities are addressed and mitigated.
immunology,biotechnology & applied microbiology